Ein Team-Meeting eines Start-ups.
Samstag, 10.11.2012 17:05 von | Aufrufe: 211

Law Office of Brodsky & Smith, LLC Announces Investigation of DUSA Pharmaceuticals, Inc. and JDA Software Group, Inc.

Ein Team-Meeting eines Start-ups. pixabay.com

PR Newswire

BALA CYNWYD, Pa., Nov. 10, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of DUSA Pharmaceuticals, Inc. ("DUSA" or the "Company") (Nasdaq- DUSA-News) relating to the proposed acquisition by Sun Pharmaceutical Industries Ltd. ("Sun").

Under the terms of the transaction, DUSA shareholders will receive only $8.00 in cash for each share of DUSA stock they own. The transaction may undervalue the Company and will not result in any substantial gain for many DUSA shareholders as DUSA stock traded at $7.00 on October 16, 2012. In addition, an analyst has set a $9.50 per share price target for DUSA.

If you own shares of DUSA stock and have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.  You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/501-dusa-dusa-pharmaceuticals-inc.html, by calling toll free 877-LEGAL-90.

Investigation of JDA Software Group, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of JDA Software Group, Inc. ("JDA Software" or the "Company") (Nasdaq- JDAS-News) relating to the proposed acquisition by RedPrairie Corporation. ("RedPrairie"). Under the terms of the transaction, JDA Software shareholders will receive only $45.00 in cash for each share on JDA Software common stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of JDA Software for not acting in the Company's shareholders' best interests in connection with the sale process to RedPrairie.

If you own shares of JDA Software stock and have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.  You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/496-jdas-jda-software-group-inc.html, by calling toll free 877-LEGAL-90.

Attorney Advertising. Past results do not guarantee a similar outcome.


ARIVA.DE Börsen-Geflüster

SOURCE Brodsky & Smith, LLC

Werbung

Mehr Nachrichten zur Dusa Pharmaceuticals Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News